<?xml version='1.0' encoding='utf-8'?>
<document id="16982285"><sentence text="A review of the receptor-binding and pharmacokinetic properties of dopamine agonists."><entity charOffset="67-75" id="DDI-PubMed.16982285.s1.e0" text="dopamine" /></sentence><sentence text="Dopamine agonists (DAs), which can be categorized as ergot derived and non-ergot derived, are used in the treatment of Parkinson's disease"><entity charOffset="0-8" id="DDI-PubMed.16982285.s2.e0" text="Dopamine" /></sentence><sentence text="" /><sentence text="This review describes the pharmacologic and pharmacokinetic properties of selected DAs and relates these characteristics to clinical outcomes, with an emphasis on adverse events" /><sentence text="" /><sentence text="Relevant articles were identified through a search of MEDLINE (to May 2006) using the terms dopamine agonists (or each individual drug name) and pbarmacokinetics, metabolism, drug-drug interaction, interactions, CYP450, fibrosis, valvular heart disease, tremor, clinical trials, reviews, and meta-analyses"><entity charOffset="92-100" id="DDI-PubMed.16982285.s6.e0" text="dopamine" /></sentence><sentence text=" Abstracts from recent sessions of the International Congress of Parkinson's Disease and Movement Disorders were also examined" /><sentence text=" Clinical studies with &lt;20 patients overall or &lt;10 patients per treatment group in the final analysis were excluded" /><sentence text=" All DAs that were graded at least possibly useful with respect to at least 3 of 4 items connected to the treatment/prevention of motor symptoms/complications in the most recent evidence-based medical review update were included" /><sentence text=" This resulted in a focus on the ergot-derived DAs bromocriptine, cabergoline, and pergolide, and the non-ergot-derived DAs pramipexole and ropinirole"><entity charOffset="51-64" id="DDI-PubMed.16982285.s10.e0" text="bromocriptine" /><entity charOffset="66-77" id="DDI-PubMed.16982285.s10.e1" text="cabergoline" /><entity charOffset="83-92" id="DDI-PubMed.16982285.s10.e2" text="pergolide" /><entity charOffset="124-135" id="DDI-PubMed.16982285.s10.e3" text="pramipexole" /><entity charOffset="140-150" id="DDI-PubMed.16982285.s10.e4" text="ropinirole" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e0" e2="DDI-PubMed.16982285.s10.e0" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e0" e2="DDI-PubMed.16982285.s10.e1" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e0" e2="DDI-PubMed.16982285.s10.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e0" e2="DDI-PubMed.16982285.s10.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e0" e2="DDI-PubMed.16982285.s10.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e1" e2="DDI-PubMed.16982285.s10.e1" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e1" e2="DDI-PubMed.16982285.s10.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e1" e2="DDI-PubMed.16982285.s10.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e1" e2="DDI-PubMed.16982285.s10.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e2" e2="DDI-PubMed.16982285.s10.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e2" e2="DDI-PubMed.16982285.s10.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e2" e2="DDI-PubMed.16982285.s10.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e3" e2="DDI-PubMed.16982285.s10.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s10.e3" e2="DDI-PubMed.16982285.s10.e4" /></sentence><sentence text="" /><sentence text="Bromocriptine, cabergoline, pergolide, and ropinirole, but not pramipexole, have the potential for drug-drug interactions mediated by the cytochrome P450 (CYP) enzyme system"><entity charOffset="0-13" id="DDI-PubMed.16982285.s12.e0" text="Bromocriptine" /><entity charOffset="15-26" id="DDI-PubMed.16982285.s12.e1" text="cabergoline" /><entity charOffset="28-37" id="DDI-PubMed.16982285.s12.e2" text="pergolide" /><entity charOffset="43-53" id="DDI-PubMed.16982285.s12.e3" text="ropinirole" /><entity charOffset="63-74" id="DDI-PubMed.16982285.s12.e4" text="pramipexole" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e0" e2="DDI-PubMed.16982285.s12.e0" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e0" e2="DDI-PubMed.16982285.s12.e1" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e0" e2="DDI-PubMed.16982285.s12.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e0" e2="DDI-PubMed.16982285.s12.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e0" e2="DDI-PubMed.16982285.s12.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e1" e2="DDI-PubMed.16982285.s12.e1" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e1" e2="DDI-PubMed.16982285.s12.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e1" e2="DDI-PubMed.16982285.s12.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e1" e2="DDI-PubMed.16982285.s12.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e2" e2="DDI-PubMed.16982285.s12.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e2" e2="DDI-PubMed.16982285.s12.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e2" e2="DDI-PubMed.16982285.s12.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e3" e2="DDI-PubMed.16982285.s12.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s12.e3" e2="DDI-PubMed.16982285.s12.e4" /></sentence><sentence text=" The occurrence of dyskinesia may be linked to stimulation of the dopamine D(1) receptor, for which cabergoline and pergolide have a similar and relatively high affinity; bromocriptine, pramipexole, and ropinirole have been associated with a lower risk of dyskinesias"><entity charOffset="66-74" id="DDI-PubMed.16982285.s13.e0" text="dopamine" /><entity charOffset="100-111" id="DDI-PubMed.16982285.s13.e1" text="cabergoline" /><entity charOffset="116-125" id="DDI-PubMed.16982285.s13.e2" text="pergolide" /><entity charOffset="171-184" id="DDI-PubMed.16982285.s13.e3" text="bromocriptine" /><entity charOffset="186-197" id="DDI-PubMed.16982285.s13.e4" text="pramipexole" /><entity charOffset="203-213" id="DDI-PubMed.16982285.s13.e5" text="ropinirole" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e0" e2="DDI-PubMed.16982285.s13.e0" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e0" e2="DDI-PubMed.16982285.s13.e1" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e0" e2="DDI-PubMed.16982285.s13.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e0" e2="DDI-PubMed.16982285.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e0" e2="DDI-PubMed.16982285.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e0" e2="DDI-PubMed.16982285.s13.e5" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e1" e2="DDI-PubMed.16982285.s13.e1" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e1" e2="DDI-PubMed.16982285.s13.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e1" e2="DDI-PubMed.16982285.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e1" e2="DDI-PubMed.16982285.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e1" e2="DDI-PubMed.16982285.s13.e5" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e2" e2="DDI-PubMed.16982285.s13.e2" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e2" e2="DDI-PubMed.16982285.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e2" e2="DDI-PubMed.16982285.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e2" e2="DDI-PubMed.16982285.s13.e5" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e3" e2="DDI-PubMed.16982285.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e3" e2="DDI-PubMed.16982285.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e3" e2="DDI-PubMed.16982285.s13.e5" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e4" e2="DDI-PubMed.16982285.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16982285.s13.e4" e2="DDI-PubMed.16982285.s13.e5" /></sentence><sentence text=" The valvular heart disease (VHD) and pulmonary and retroperitoneal fibrosis seen with long-term use appear to represent a class effect of the ergot-derived DAs that may be related to stimulation of serotonin 5-HT(2B) (and possibly 5-HT(2A)) receptors" /><sentence text=" The incidence of valvular regurgitation was 31% to 47% with ergot-derived DAs, 10% with non-ergot-derived DAs, and 13% with controls" /><sentence text="" /><sentence text="As reflected in the results of the clinical trials included in this review, dyskinesia associated with DA therapy may be linked to stimulation of the D(1) receptor" /><sentence text=" Fibrosis (including VHD) seemed to be a class effect of the ergot-derived DAs" /><sentence text=" Each of the DAs except pramipexole has the potential to interact with other drugs via the CYP enzyme system"><entity charOffset="24-35" id="DDI-PubMed.16982285.s19.e0" text="pramipexole" /></sentence><sentence text="" /></document>